Phase 1/2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × fludarabine phosphate × Clear all
NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Ossium Health, Inc.

Phase 1/2 Recruiting
12 enrolled
NCT03128034 2025-12-19

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
75 enrolled
NCT03670966 2025-10-16

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
30 enrolled
NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT00027820 2019-12-20

Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
106 enrolled
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
NCT01163201 2017-12-02

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
NCT00365287 2017-11-29

Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

Masonic Cancer Center, University of Minnesota

Phase 1/2 Completed
148 enrolled
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00448357 2017-07-17

LCCC0510

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
54 enrolled 17 charts
NCT00003619 2013-06-26

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed